Why Is the Medical Device Registration Timeline in Japan Extended? | FAQ

Why Is the Medical Device Registration Timeline in Japan Extended?

Published: 15 July 2026, 19:16  |  Updated: 15 July 2026, 19:16

Direct answer: Registration timelines in Japan are most often extended because the product classification, the applicable regulatory pathway, or the scope of the existing documentation does not match Japanese requirements before submission. Typical causes include an incorrect risk classification or pathway decision, technical files and evidence chains that are incomplete or internally inconsistent, quality management system (QMS) and manufacturing-site documentation that does not cover the submitted models, unclear arrangements for the Marketing Authorization Holder (MAH) and local representative, insufficient or non-transferable clinical evidence, and unplanned translation, notarisation or labelling work. A structured documentation gap assessment completed before formal submission is the most effective way to prevent these delays.

For a Chinese medical device manufacturer, the most reliable approach is to complete product classification and a documentation gap assessment first, and then determine whether existing NMPA, CE, FDA, ISO 13485 or other market documentation can be reused. Registration in a target market affects technical documentation, authorised representation, importer cooperation, labelling language, QMS evidence and subsequent change maintenance at the same time. If a project is driven only by a list of documents to be submitted, deficiency letters and rework are likely to arise in model coverage, evidence chain consistency, labelling claims and control of certificates. AIMEILI recommends that companies plan this question as part of a GHWP member state and multi-country market access strategy, using one reusable core technical file to support localisation in different markets rather than rebuilding documentation country by country.

Content Structure

• Key Summary
• Applicable Scenarios and Core Questions
• Registration Decision Logic
• Documentation and Evidence
• Common Pitfalls
• Company Preparation Checklist
• AIMEILI's View
• Frequently Asked Follow-Up Questions
• Continued Reading
• Scope of Application

Key Summary

On the question of why the medical device registration timeline in Japan is extended, companies should first confirm the target country, the product risk class, the applicable regulatory pathway and the existing documentation base, and then assess technical documentation, quality management system, labelling and instructions for use, local representative, clinical evidence and post-market maintenance requirements. AIMEILI recommends completing a documentation gap assessment before formal submission to avoid a prolonged project timeline caused by unclear classification, documentation or authorisation arrangements. For Chinese medical device manufacturers, the more reliable approach is to complete product classification and a documentation gap assessment first, then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused.

Registration in a target market generally affects technical documentation, authorised representative, importer cooperation, labelling language, quality system evidence and subsequent change maintenance at the same time. If a project is driven only by which documents must be submitted, deficiency letters and rework are likely to occur in model coverage, evidence chain consistency, labelling claims and control of certificates. AIMEILI recommends planning this question within a GHWP member state and multi-country market access strategy, using one reusable core technical file to support localisation in different markets rather than redoing documentation on an ad hoc basis in each country.

Applicable Scenarios and Core Questions

Companies searching for why the medical device registration timeline in Japan is extended are usually not looking for a conceptual explanation. Their real questions are whether their existing documentation can support a submission in the target market, whether a local representative or authorised representative is required, why the timeline is being extended, and which issues could affect the launch plan. This question typically involves product classification, registration pathway, evidence chain, labelling localisation and post-market maintenance responsibilities at the same time.

If a company plans to enter several GHWP member states or markets in Southeast Asia, the Middle East and Latin America simultaneously, answering the process for one country alone is not sufficient. A more valuable approach is to first produce reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence, labelling and instructions for use, and then adapt them to local regulatory requirements in each country.

Registration Decision Logic

Companies should first confirm the intended use, mechanism of action, use environment, method and duration of contact with the human body, sterility, whether the device is active, and whether it contains software or has an IVD attribute, and then determine the risk class and the submission pathway. If the pathway decision is wrong, all subsequent translation, notarisation, authorisation, testing and supplementary documentation will move in the wrong direction.

For a target market project, the applicant entity and the boundaries of local responsibility must also be confirmed: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market events, who initiates changes, and who maintains renewal documentation. If these questions are left vague in commercial contracts only, market control can easily be affected later.

Documentation and Evidence

Typical documentation includes the product description, model and specification matrix, intended use, basis for risk classification, ISO 13485 or applicable quality system evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labelling and instructions for use, authorisation documents, existing registration certificates, manufacturer's declarations and post-market surveillance documentation.

The critical factor in documentation quality is not volume but consistency. Claims in the instructions for use, the models covered by test reports, the scope of application of clinical evidence, risk management conclusions, label warnings and the information on the registration application form must support one another. Regulators focus on whether the device is safe, effective and traceable for its intended use, not on how many documents have been uploaded. If documentation is submitted without aligning the evidence or establishing who is responsible locally, the registration timeline will almost certainly be extended by deficiency letters and repeated clarification.

Common Pitfalls

The most common problem is treating registration as a simple document submission exercise without first clarifying product classification, evidence coverage and local responsibility relationships. This is one of the main reasons the registration timeline in Japan is extended.

• Submitting a direct translation of domestic NMPA documentation without rearranging the evidence according to the target market pathway.
• Listing too many models and specifications while test reports, clinical evidence or labelling do not cover them adequately.
• Selecting a local representative purely on the basis of sales cooperation, without defining regulatory responsibility, certificate control and post-market maintenance obligations.
• Inconsistency between labels, instructions for use, promotional materials and registration documentation, leading to deficiency letters or post-market compliance risk.
• Failing to plan multi-country documentation reuse in advance, resulting in duplicated preparation in every country and inflated cost and timeline.

Company Preparation Checklist

Before starting a project, companies should use an internal checklist to confirm the documentation base, so that critical evidence gaps are not discovered only after the submission has begun.

• Compile the target product list, model and specification matrix and intended use statements.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management file, clinical evaluation and English instructions for use.
• Confirm the responsibilities, fees, certificate control and exit mechanism of the local representative or authorised representative.
• Establish a gap assessment table for the target country, identifying what must be retested, translated, notarised or supported by additional declarations.

AIMEILI's View

AIMEILI recommends that companies view target market registration not as a one-off document submission but as an overseas market access programme. For companies preparing to enter multiple countries, building a clear core technical file and evidence matrix first and then converting it to national requirements is usually faster, more stable and more conducive to subsequent changes and certificate renewals than filling documentation gaps country by country at short notice.

From a project management perspective, three things should be controlled in advance: first, product classification and pathway determination; second, consistency of the documentation and evidence chain; third, the regulatory responsibility boundaries of local partners. Unless these three items are clear, a project may still face repeated setbacks during deficiency response, agent communication and post-market maintenance, no matter how extensive the documentation appears to be.

Frequently Asked Follow-Up Questions

Can domestic documentation be used directly for registration in a target market?

Domestic documentation can serve as the basis, but it generally cannot be submitted as-is. Companies need to adjust the documentation structure, language, labelling, authorisation documents and evidence chain in accordance with local regulatory requirements before submission.

When is the best time to start a gap assessment?

A gap assessment should be started as soon as the target market and product list are confirmed. The earlier it is completed, the easier it is to schedule retesting, translation, labelling adjustments and representative selection in advance.

Why does the choice of local representative affect registration quality?

The local representative usually participates in regulatory communication, change notifications, certificate renewal and post-market event handling. If responsibilities and rights are unclear, certificate control and long-term market stability can be affected.

Implementation Recommendations

When executing a registration project of this type, companies should establish a project register that manages the product list, model and specification matrix, registration pathway, documentation owners, translation status, testing status, local representative communication records and expected submission dates in a single table. This makes documentation gaps visible in good time and helps management judge whether the project will affect the launch plan.

Companies that already hold registrations in several countries should also build an evidence reuse matrix, defining which documents can serve as core evidence and which must be reissued or supported by additional explanations under national requirements. Labelling and instructions for use, clinical evaluation, risk management, performance verification and quality system certificates must in particular be kept at consistent versions.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Define the local representative and certificate control.
• Track translation, notarisation, testing and deficiency response status.
• Assign post-market maintenance responsibilities in advance.

Quality Management System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulators normally check whether the manufacturer name, manufacturing site, product scope, certificate validity period, applicable standards and technical file are consistent with one another. If the scope covered by the ISO 13485 certificate does not match the product being submitted, or if the manufacturing site, model and specification range and version of the instructions for use do not match the test reports, additional explanations may be requested even when a large volume of documentation has been prepared.

Companies should establish an evidence consistency checklist before submission, mapping product name, model and specification, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labelling and instructions for use version, and quality system certificate item by item. This appears basic, but it measurably reduces the probability of deficiency letters, particularly for projects submitting simultaneously in several GHWP member states or for several product families.

Localisation and Local Representative Responsibilities

Target market registration projects usually involve arrangements with a local representative, authorised representative, importer or registration holder. Companies need to confirm in advance whether the local partner is responsible only for submitting documents, or also for regulatory communication, certificate maintenance, post-market event reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and long-term market stability.

Labelling, instructions for use and authorisation documents also cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings and cautions, storage and transport conditions, UDI or traceability requirements, importer information, authorised representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localisation is converting reusable evidence into a submission structure acceptable in the target country, rather than writing a separate, isolated set of documents.

Post-Market Maintenance and Long-Term Planning

Completion of registration does not mean that compliance work is finished. Companies must also maintain certificate validity, change records, distributor authorisations, complaint handling, adverse event reporting, recall procedures, label versions and records of regulatory updates. Many companies invest heavily in obtaining the certificate but neglect post-market maintenance, and then find that the certificate no longer matches actual marketing once a manufacturing site change, model extension, instructions for use update or representative change occurs.

AIMEILI recommends managing this question within an annual international registration plan: first define target market priorities, then build a reusable documentation package and a national gap list, and finally schedule submission, deficiency response, post-market maintenance and renewal milestones. The value of this approach is not only higher efficiency for a single country registration; more importantly, it allows companies to build a repeatable compliance capability for going global and reduces the cost of starting documentation preparation from scratch each time they enter a new market.

Continued Reading

Previous

• How Are Responsibilities Allocated for an Authorised Representative for Medical Device Registration in Japan?

Next

• What Are the Common Reasons for Deficiency Letters in Medical Device Registration in Japan?

Recommended Reading

• How Should a Local Representative Be Selected for Medical Device Registration in Brazil?
• How Are Responsibilities Allocated for an Authorised Representative for Medical Device Registration in Brazil?
• Why Is the Medical Device Registration Timeline in Brazil Extended?
• What Are the Common Reasons for Deficiency Letters in Medical Device Registration in Brazil?
• How Is Post-Market Surveillance Conducted for Medical Device Registration in Brazil?
• When Must a Registration Change Be Filed for Medical Device Registration in Brazil?

Content Review and Scope of Application

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team.

Source principle: Priority is given to official regulatory authorities, international organisations, standards bodies and publicly available regulatory materials; industry media and project experience are used only as supporting judgement.

Scope of application: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal advice. Specific projects should be based on the latest requirements of the target country's regulatory authority and the company's actual product documentation. This article was compiled with reference to AIMEILI's regulatory practice experience and publicly available regulatory information.